ArticleMediterranean journal of rheumatology2025
Calcinosis Universalis: An Atypical Presentation of Mi-2 Positive Juvenile Dermatomyositis - A Case-Based Review.
Article in Mediterranean journal of rheumatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Calcinosis Cutis as the Leading Manifestation of Juvenile Dermatomyositis: A Case Report.Case reports in dermatologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Juvenile Dermatomyositis (JDM) is a systemic autoimmune disease in children, characterised by skin and muscle inflammation, with incidence of 1.6 to 4 cases per million children annually. Calcinosis, affecting 20% to 70% of JDM patients, can lead to significant morbidity. The association of calcinosis with anti-Mi-2 antibodies is rare and complicates management. Case: We present a rare case of a 12-year-old girl diagnosed with JDM, extensive calcinosis, and positive anti-Mi-2 antibodies. The patient exhibited significant muscle weakness, skin manifestations, and painful calcinosis leading to contractures. Initial management included tofacitinib and intravenous pamidronate, resulting in no new calcinosis formation. Discussion: A comprehensive review of existing literature highlights the rarity of calcinosis in anti-Mi-2 positive patients. While traditional treatments have shown variable effectiveness, emerging therapies like JAK (Janus Kinase) inhibitors may offer new avenues for management. The literature underscores the need for personalised treatment strategies given the atypical presentations and outcomes. Conclusion: This case adds to the limited documentation of calcinosis in JDM with anti-Mi-2 antibodies, emphasising the need for increased awareness and research. Personalised treatment approaches are crucial, and future studies should focus on larger datasets and emerging therapeutic modalities to optimise management and improve patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.